Xianming Liu

ORCID: 0000-0003-1574-8102
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders
  • Gastric Cancer Management and Outcomes
  • CNS Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Immune Cell Function and Interaction
  • Bariatric Surgery and Outcomes
  • Multiple and Secondary Primary Cancers
  • Cancer Immunotherapy and Biomarkers
  • Ovarian cancer diagnosis and treatment
  • CAR-T cell therapy research
  • Gastrointestinal Tumor Research and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Medical Imaging Techniques and Applications
  • Reproductive tract infections research
  • Diet and metabolism studies
  • Chemotherapy-related skin toxicity
  • Cancer, Lipids, and Metabolism
  • Neutropenia and Cancer Infections
  • Diabetes Treatment and Management
  • Cancer Treatment and Pharmacology
  • Brain Metastases and Treatment
  • Thyroid Disorders and Treatments
  • Advanced Breast Cancer Therapies

Qingdao University
2013-2025

Qingdao Municipal Hospital
2017-2025

Tianjin Medical University Cancer Institute and Hospital
2010-2023

Hebei North University
2022-2023

Sichuan Mianyang 404 Hospital
2023

Fifth Hospital of Shijiazhuang
2022

Hebei General Hospital
2022

National Clinical Research
2021

Jinan University
2020

Inner Mongolia Comprehensive Disease Prevention and Control Center
2018

// Ling Dong 1, * , Huijuan Lv Wei Li 1 Zheng Song Lanfang Shiyong Zhou Lihua Qiu Zhengzi Qian Xianming Liu Lixia Feng Bin Meng 2 Kai Fu 3 Xi Wang 4 Qiang Pan-Hammarström 5 Ping 6 Xianhuo Huilai Zhang Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute Hospital, National Clinical Research Cancer, Key Laboratory Prevention Therapy, Tianjin, China Pathology, Pathology Microbiology Internal Medicine, Nebraska Center, Omaha, NE, USA...

10.18632/oncotarget.9061 article EN Oncotarget 2016-04-27

Relatively little information is available on quantitative risks of therapy-induced second malignant neoplasm (SMN) in patients with non-Hodgkin lymphoma (NHL). A nested case-control study was conducted a cohort 3412 treated for NHL between 1990 and 2006, including 118 SMN 472 controls. Risks leukemia/lung/breast/colorectal bladder cancer were higher compared the general population. risk leukemia restricted to given cumulative dose cyclophosphamide more than 11 250 mg/m(2). However, no...

10.3109/10428194.2012.743657 article EN Leukemia & lymphoma/Leukemia and lymphoma 2012-10-26

The BCL6 (B-Cell Lymphoma 6) gene is a proto-oncogene that often expressed in diffuse large B-cell lymphomas (DLBCLs). loss of function can kill DLBCL cells, demonstrating necessary for the survival cells and could be therapeutic target. In this study, we found protein levels were consistently upregulated tissues, whereas its mRNA varied randomly suggesting post-transcriptional mechanism was involved regulation. We used bioinformatics analysis to search miRNAs, which potentially target BCL6,...

10.1007/s13238-016-0316-z article EN cc-by Protein & Cell 2016-11-04

Persistent infection and prolonged shedding of human bocavirus 1 (HBoV1) in children have been reported, the role HBoV1 as a sole causative pathogen acute respiratory (ARI) is yet to be established. While reported prevalence HBoV varies due different detection methods sampling criteria, determining viral bacterial etiology using multiplex real-time PCR reported. Herein, we aimed further explore pathogenicity patients with ARI by screening infections Qingdao comparing epidemiological,...

10.3389/fmicb.2022.935688 article EN cc-by Frontiers in Microbiology 2022-08-10

Follicular lymphoma (FL), the most common indolent lymphoma, is a clinically and genetically heterogeneous disease. However, prognostic value of driver gene mutations copy number alterations has not been systematically assessed. Here, we analysed clinical-biological features 415 FL patients to identify variables associated with disease progression within 24 months first-line therapy (POD24). Patients B symptoms, elevated lactate dehydrogenase β2-microglobulin levels, unfavourable baseline...

10.1111/bjh.18974 article EN British Journal of Haematology 2023-07-16

Abstract De novo CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is increasingly recognized as a distinct pathologic phenomenon with specific clinical picture. However, CD5+ DLBCL has not been studied on scale in China. In this study, we show that occurs at low frequency (9.2%). Comparison of characteristics vs CD5− showed was more frequently elderly (>60 years) and had B symptoms, high‐performance status, stage III‐IV, an IPI score >2 bone marrow involvement. Patients tumours...

10.1002/hon.2657 article EN Hematological Oncology 2019-07-30

Leptomeningeal metastasis is an uncommon but devastating complication. The incidence of non-Hodgkin's lymphoma has been increasing in recent decades, due to the poor central nervous system penetration drugs and prolonged overall survival patients, leptomeningeal metastases gradually increased over time. Patients with have short durations quality life; there are few studies about metastases. We investigated characteristics outcomes patients This study included 27 diagnosed at Tianjin Medical...

10.1007/s10147-018-1268-5 article EN cc-by International Journal of Clinical Oncology 2018-03-20

Diffuse large B-cell lymphoma (DLBCL) presents a great clinical challenge and has poor prognosis, with immune-related genes playing crucial role. We aimed to develop an prognostic signature for improving prognosis prediction in DLBCL. Samples from the GSE31312 dataset were randomly allocated discovery internal validation cohorts. Univariate Cox, random forest, LASSO regression multivariate Cox analyses utilized signature, which was verified cohort, entire cohort external (GSE10846). The...

10.18632/aging.203587 article EN cc-by Aging 2021-10-05

Background Up the reproductive tract, there are large differences in composition of vaginal microbes. Throughout menstrual cycle, structure microbiome shifts. Few studies have examined both combination. Our study was designed to explore trends different parts vagina healthy women over cycle. Methods We performed metagenomic sequencing characterize between cervical orifice and mid-vagina throughout Results results showed similar during periovulatory luteal phases, with Lactobacillus being...

10.7717/peerj.16438 article EN cc-by PeerJ 2023-12-01

The type 2 diabetes mellitus (T2DM) is one of the most serious diseases that threaten public health. Modified gastric bypass surgery has been applied to treatment T2DM patients in 1990s, but therapeutic mechanism this function still unclear. aim study was further clarify effect and modified on glucose metabolism with T2DM. In study, incretin indexes blood were analyzed before 1 week 1, 3, 6 months after surgery. results suggested Roux-en-Y can promote GLP-1 secretion T2DM, while reducing...

10.1155/2015/625196 article EN cc-by Gastroenterology Research and Practice 2015-01-01

A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing miR-150 expression clinicopathological characteristics patients with PGI-DLBCL. total 84 diagnosed PGI-DLBCL were recruited both tumor adjacent non-tumor tissue samples collected. was assessed via reverse transcription-quantitative (RT-q)PCR analysis. results...

10.3892/ol.2020.11452 article EN Oncology Letters 2020-03-10

Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) is a highly heterogeneous type of non-Hodgkin lymphoma. A number studies have demonstrated that microRNA-130a (miR-130a) serves role in the tumorigenesis and prognosis numerous human tumors. However, to best our knowledge, prognostic significance miR-130a PGI-DLBCL remains unknown. The present study explored association between clinical outcomes PGI-DLBCL. Relative expression was assessed by reverse transcription-quantitative...

10.3892/ol.2020.11954 article EN Oncology Letters 2020-08-06

The data about the clinical features and outcomes of Chinese patients with follicular lymphoma (FL) are limited. Here, we conducted a retrospective study to explore initial treatment strategies FL in real world.This included who were newly diagnosed Tianjin Medical University Cancer Institute Hospital from March 2002 August 2020.A total 926 enrolled. median age was 54 years old, majority had advanced-stage disease Eastern Cooperative Oncology Group(ECOG) <1 but less frequently infiltrated...

10.3389/fonc.2022.863021 article EN cc-by Frontiers in Oncology 2022-09-16

Secondary central nervous system (SCNS) involvement is an infrequent but universally fatal event in diffused large B-cell lymphoma. The occurrence rate of SCNS approximately 5% comes with a poor prognosis ever after. However, existing risk models to predict the incidence and these patients lack both efficiency accuracy. Controversy has also been reported regarding which factor may best identify population high CNS relapse rate. In this study, we retrospectively analyzed 831 lymphoma,...

10.1002/hon.2928 article EN Hematological Oncology 2021-09-26
Coming Soon ...